INBX
Inhibrx BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical readouts or a favorable partnership that improves funding can materially de‑risk the lead programs and drive a multi‑month re‑rating toward the bull target.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -9.1.
What can break
Adverse or inconclusive clinical data, partner delays, or the need for dilutive financing would push the stock toward the bear target as risk premia and liquidity pressures increase.
Momentum
88
Value
44
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.92 · Bull $2.88 · Bear $1.15
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $36.00
Why
Momentum88 · Δ7d -9.1
Value44 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
88
34% active weight
Current posture
7d trendSoftening
Δ7d
-9.1
Δ21d
-11.4
Value
44
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 87.6 / Value 44.4 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.46B
Beta
-
Shares Out
14.54M
P/E (TTM) · Derived
0.9
P/S (TTM)
798.66
P/FCF (TTM) · Derived
-10.80
Rev YoY
+1200.0%
EPS YoY
+19.7%
Gross Margin
-
Op Margin
-11002.1%
Net Debt
-$152.6M
Current Ratio
4.49
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology